| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the National Institute of Neurological Disorders and Stroke (Drs. Ravina, Hart, Murphy, and Marler) National Institutes of Health, Rockville, MD; Department of Pharmacology (Dr. Fagan), Medical College of Georgia, Augusta; Departments of Pharmacy and Neurology (Dr. Hovinga), Cleveland Clinic Foundation, OH; and Johns Hopkins University School of Medicine (Dr. Dawson), Baltimore, MD.
Address correspondence to Dr. Bernard M. Ravina, NINDS, Neuroscience Center, Rm 2225, 6001 Executive Blvd, Rockville, MD 20892-9257; e-mail: RavinaB{at}ninds.nih.gov
Background: Current therapies for PD ameliorate symptoms in the early phases of disease but become less effective over time, as the underlying disease progresses. Therapies that slow the progression of PD are needed. However, there have been relatively few clinical trials aimed at demonstrating neuroprotection. The authors sought to identify potential neuroprotective agents for testing in clinical trials.
Methods: First a broad array of compounds were identified by working with clinicians and researchers in academics and industry. Specific criteria were drafted for drug evaluation, including scientific rationale, blood–brain barrier penetration, safety and tolerability, and evidence of efficacy in animal models or humans. Agents were prioritized based on these criteria.
Results: The authors identified 59 potential neuroprotective compounds, proposed by 42 clinicians and scientists from 13 countries. After systematic reviews using the specified criteria they found 12 compounds to be attractive candidates for further clinical trials in PD.
Conclusions: Several potential neuroprotective compounds, representing a wide range of mechanisms, are available and merit further investigation in PD.
This article has been cited by other articles:
|
|
 |
|
  K. Hayakawa, K. Mishima, M. Nozako, M. Hazekawa, S. Mishima, M. Fujioka, K. Orito, N. Egashira, K. Iwasaki, and M. Fujiwara Delayed Treatment With Minocycline Ameliorates Neurologic Impairment Through Activated Microglia Expressing a High-Mobility Group Box1-Inhibiting Mechanism Stroke, March 1, 2008; 39(3): 951 - 958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Ahlskog I can't get no satisfaction: Still no neuroprotection for Parkinson disease Neurology, October 9, 2007; 69(15): 1476 - 1477. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Zhang, V. Anantharam, A. Kanthasamy, and A. G. Kanthasamy Neuroprotective Effect of Protein Kinase C{delta} Inhibitor Rottlerin in Cell Culture and Animal Models of Parkinson's Disease J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 913 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ritz, A. Ascherio, H. Checkoway, K. S. Marder, L. M. Nelson, W. A. Rocca, G. W. Ross, D. Strickland, S. K. Van Den Eeden, and J. Gorell Pooled Analysis of Tobacco Use and Risk of Parkinson Disease Arch Neurol, July 1, 2007; 64(7): 990 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Mitsumoto Mitochondrial Nutrition as a Strategy for Neuroprotection in Parkinson's Disease--Research Focus in the Department of Alternative Medicine and Experimental Therapeutics at Hokuriku University Evid. Based Complement. Altern. Med., June 1, 2007; 4(2): 263 - 265. [Full Text] [PDF]
|
|
|
|
|
|
B. C. Tilley and W. R. Galpern Screening Potential Therapies: Lessons Learned From New Paradigms Used in Parkinson Disease Stroke, February 1, 2007; 38(2): 800 - 803. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bender, W. Koch, M. Elstner, Y. Schombacher, J. Bender, M. Moeschl, F. Gekeler, B. Muller-Myhsok, T. Gasser, K. Tatsch, et al. Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial. Neurology, October 10, 2006; 67(7): 1262 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Caccia, R. Maj, M. Calabresi, S. Maestroni, L. Faravelli, L. Curatolo, P. Salvati, and R. G. Fariello Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology, October 10, 2006; 67(7 Suppl 2): S18 - S23. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. E DLUZEN and J. L MCDERMOTT Estrogen, Testosterone, and Methamphetamine Toxicity. Ann. N.Y. Acad. Sci., August 1, 2006; 1074: 282 - 294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Traynor, L. Bruijn, R. Conwit, F. Beal, G. O'Neill, S. C. Fagan, and M. E. Cudkowicz Neuroprotective agents for clinical trials in ALS: A systematic assessment. Neurology, July 11, 2006; 67(1): 20 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kieburtz Issues in neuroprotection clinical trials in Parkinson's disease Neurology, May 23, 2006; 66(10_suppl_4): S50 - S57. [Abstract] [Full Text]
|
|
|
|
|
|
R. A. Hauser and T. A. Zesiewicz Clinical trials aimed at detecting neuroprotection in Parkinson's disease Neurology, May 23, 2006; 66(10_suppl_4): S58 - S68. [Abstract] [Full Text]
|
|
|
|
|
|
C. W. Olanow Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease Neurology, May 23, 2006; 66(10_suppl_4): S69 - S79. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. J. Chen and A.-V. Ly Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease Am. J. Health Syst. Pharm., May 15, 2006; 63(10): 915 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Tilley, Y. Y. Palesch, K. Kieburtz, B. Ravina, P. Huang, J. J. Elm, K. Shannon, G. F. Wooten, C. M. Tanner, G. C. Goetz, et al. Optimizing the ongoing search for new treatments for Parkinson disease: Using futility designs Neurology, March 14, 2006; 66(5): 628 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The NINDS NET-PD Investigators A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease Neurology, March 14, 2006; 66(5): 664 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Xu, Y. Xu, D. Brown-Jermyn, J.-F. Chen, A. Ascherio, D. E. Dluzen, and M. A. Schwarzschild Estrogen Prevents Neuroprotection by Caffeine in the Mouse 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease J. Neurosci., January 11, 2006; 26(2): 535 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Guimaraes, K. Kieburtz, C. G Goetz, J. J Elm, Y. Y Palesch, P. Huang, B. Ravina, C. M Tanner, and B. C Tilley Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials Clinical Trials, December 1, 2005; 2(6): 509 - 518. [Abstract] [PDF]
|
|
|
|
 |
|
 J. G. Nutt and G. F. Wooten Diagnosis and Initial Management of Parkinson's Disease N. Engl. J. Med., September 8, 2005; 353(10): 1021 - 1027. [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Chen and D. M. Swope Clinical Pharmacology of Rasagiline: A Novel, Second-Generation Propargylamine for the Treatment of Parkinson Disease J. Clin. Pharmacol., August 1, 2005; 45(8): 878 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Levy, E. D. Louis, L. Cote, M. Perez, H. Mejia-Santana, H. Andrews, J. Harris, C. Waters, B. Ford, S. Frucht, et al. Contribution of Aging to the Severity of Different Motor Signs in Parkinson Disease Arch Neurol, March 1, 2005; 62(3): 467 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ascherio, M. G. Weisskopf, E. J. O'Reilly, M. L. McCullough, E. E. Calle, C. Rodriguez, and M. J. Thun Coffee Consumption, Gender, and Parkinson's Disease Mortality in the Cancer Prevention Study II Cohort: The Modifying Effects of Estrogen Am. J. Epidemiol., November 15, 2004; 160(10): 977 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. LeWitt Clinical trials of neuroprotection for Parkinson's disease Neurology, October 12, 2004; 63(7_suppl_2): S23 - S31. [Full Text]
|
|
|
|
|
|
E. Diguet, C. E. Gross, E. Bezard, F. Tison, N. Stefanova, G. K. Wenning, B. Ravina, S. Fagan, R. Hart, C. Hovinga, et al. Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment Neurology, January 13, 2004; 62(1): 158 - 159. [Full Text] [PDF]
|
|
|
|
|
|
C. W. Shults Treatments of Parkinson Disease: Circa 2003 Arch Neurol, December 1, 2003; 60(12): 1680 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Feigin Nondopaminergic symptomatic therapies for Parkinson's disease: Turn on or turn off? Neurology, August 12, 2003; 61(3): 286 - 287. [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
